SEB Equities analyst Jakob Lembke initiated coverage of Xvivo Perfusion with a Buy rating and SEK 410 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly